Related Experiment Video

Updated: Jun 23, 2026

In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium
10:18

In Vivo Gene Transfer to the Rabbit Common Carotid Artery Endothelium

Published on: May 6, 2018

Transcriptional targeting of tumor endothelial cells for gene therapy

Zhihong Dong1, Jacques E Nör

  • 1Angiogenesis Research Laboratory, Department of Restorative Sciences, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA.

Advanced Drug Delivery Reviews
|April 28, 2009
PubMed

Insights

Targeting tumor endothelial cells via transcriptional control offers a promising cancer gene therapy approach. This strategy aims to minimize toxicities associated with anti-angiogenic treatments by selectively delivering therapeutic genes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Angiogenesis is crucial in tumor development and a target for cancer therapy.
  • Current anti-angiogenic treatments face challenges due to off-target toxicities.
  • Transcriptional targeting of tumor endothelial cells (TECs) presents a novel therapeutic strategy.

Purpose of the Study:

  • To review promoters, vectors, and genes for transcriptional targeting of TECs.
  • To discuss the potential of this approach in cancer gene therapy.
  • To highlight strategies for enhancing specificity and efficacy.

Main Methods:

  • Identification and characterization of genes specifically expressed in tumor-associated endothelial cells.
  • Utilizing specific promoters for selective gene expression in TECs.
  • Review of various vector systems for gene delivery to TECs.

Main Results:

  • Several genes specific to tumor-associated endothelial cells have been identified.
  • Promoters driving selective gene expression in TECs have been characterized.
  • Various gene therapy vectors are being explored for this application.

Conclusions:

  • Transcriptional targeting of TECs holds significant promise for cancer gene therapy.
  • This approach may overcome limitations of current anti-angiogenic therapies.
  • Further research into promoters, vectors, and therapeutic genes is essential for clinical translation.

More Related Videos

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Characterization of Blood Outgrowth Endothelial Cells (BOEC) from Porcine Peripheral Blood08:02

Characterization of Blood Outgrowth Endothelial Cells (BOEC) from Porcine Peripheral Blood

Published on: January 6, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...